Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors

Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ

(2013) Christian Schürch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

(2012) Elizabeth S. Nakasone et al.   CANCER CELL

The tumor microenvironment is a dominant force in multidrug resistance

(2012) Ana Luísa Correia et al.   DRUG RESISTANCE UPDATES

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

(2010) Deborah L. White et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of an IL7-R+c-Kithi myelolymphoid progenitor critically dependent on IFN-γ signaling during acute malaria

(2010) Nikolai N Belyaev et al.   NATURE IMMUNOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARγ ligand troglitazone

(2009) K. von Schwarzenberg et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Interferon-γ-mediated pathways are induced in human CD34+ haematopoietic stem cells

(2009) Katharina Kurz et al.   IMMUNOBIOLOGY

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Brief Report: Interferon-γ Induces Expansion of Lin−Sca-1+C-Kit+Cells

(2009) Xin Zhao et al.   STEM CELLS

Treatment selection after imatinib resistance in chronic myeloid leukemia

(2009) Elias Jabbour et al.   Targeted Oncology

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance

(2008) C. Roche-Lestienne et al.   BLOOD